CLAIMS

1. Compound for the prevention and/or the treatment of allergy consisting of at least one allergen antigenic determinant which is recognised by a B cell or an antibody secreted by a B cell of a non-atopic individual to said allergen and at least one antigenic determinant of an antigen different from said allergen which triggers T cell activation.

2. Compound for the prevention and/or the treatment of allergy comprising a nucleotide sequence encoding both antigenic determinants of the compound according to claim 1, said sequence being possibly linked to one or more regulatory sequence(s) active into a patient's cell.

3. Compound according to claim 1 or 2, wherein said allergen antigenic determinant is not recognised by a T cell.

4. Compound according to any of the claims 1 to 3, wherein the allergen is selected from the group consisting of the following main allergens : *Der pI* and *Der pII* of house dust mite *Dermatophagoides pteronyssinus*, the major antigen of *Aspergillus fumigatus*, the staphylococcal B enterotoxin (SEB) and the bovine β-lactoglobulin.

5. Compound according to any of the claims 1 to 4, wherein the antigenic determinant of the antigen which triggers T cells activation is a T cell epitope of tetanus toxoid, diphteria, mycobacterium, influenza or measles virus antigens.

6. Compound according to any one of the preceding claims, wherein the allergen antigenic determinant and the antigenic determinant of the antigen

are peptidic sequences, preferably bound together, by a peptidic linker.

7. Compound according to claim 6, wherein the linker is made of at least two amino-acids.

8. Compound according to ~~any of the preceding claims~~ claim 1, characterised in that the compound is selected from the group consisting of the peptides having the following aminoacid sequences :

SEQ ID NO. 1 :

QYIKANSKFIGITELGGHEIKKVLVPGCHGS

SEQ ID NO. 2 :

HEIKKVLVPGCHGS

SEQ ID NO. 3 :

DQYIKANSKFIGITELGGQYIKANSKFIGITELSSCHGSEPCIIHRGKPFGGCHGSEPC
IIHRGKPFSSCHGSEPCIIHRGKPFGGCHGSEPCIIHRGKPFSSCHGSEPCIIHRGKPF
GGCHGSEPCIIHRGKPFSR

SEQ ID NO. 4 :

PKYVKQNTLKLATGKKGPKYVKQNTLKLATGKKGVIIGIK

SEQ ID NO. 5 :

QYIKANSKFIGITELGGCHGSEPCNIHRGKPF

or a nucleotidic sequence encoding at least one of said amino-acids sequences, preferably the sequence SEQ ID NO. 6

GAATTCCCACCATGGATCAGTATATAAAAGCAAATTCTAAATTTATAGGTATAACTGAA
CTAGGAGGTTGCCATGGTTCAGAACCATGTATCATTCATCGTGGTAAACCATTCGGCGG
TTGTCACGGAAGTGAGCCTTGCATTATACACAGAGGAAAGCCGTTCTAAGCGGCCGC.

9. Pharmaceutical composition comprising the compound according to ~~any one of the preceding claims~~ claim 1 and a pharmaceutically acceptable carrier.

10. Cosmetical composition comprising the compound according to ~~any one of the claims 1 to 8~~ claim 1 and a cosmetical acceptable carrier.

11. Beverage, ~~food~~ and/or feed composition comprising the compound according to ~~any one of the claims 1 to 8~~ claim 1 and a liquid, food and/or feed acceptable carrier.

12. Compound according to ~~any of the claims 1 to 8~~ claim 1 for use as a medicament.

13. Use of the compound according to any of the claims 1 to 8 or the pharmaceutical composition according to claim 9 for the manufacture of a medicament in the prevention and/or the treatment of allergy or of a disease of allergic origin, particularly immediate hypersensitivity allergy.

14. Use according to claim 13, wherein the disease is selected from the group consisting of rhinitis and sinusitis of allergic origin, bronchial asthma, atopic dermatitis, some forms of acute and chronic urticaria, gastro-intestinal syndromes associated with the ingestion of food allergens, the so-called oro-pharyngeal syndrome of the same origin, anaphylactic reactions associated with drug hypersensitivities and/or a mixture thereof.

Sub A'

Add B'

add C17

add E2